Skip to main content
. 2022 Apr 12;15:3977–3989. doi: 10.2147/IJGM.S352536

Figure 1.

Figure 1

Flow chart of the retrospective study of anlotinib combined with PD-1 blockades in the treatment for patients with previously treated epithelial ovarian cancer.